Abstract
The introduction of paramagnetic contrast in the late 1980s constituted a paradigm
shift boosting the efficacy of magnetic resonance imaging. Due to its high magnetic
moment, gadolinium-based contrast agent made its way smoothly as the flagship paramagnetic
contrast. With the widespread application, reports of untoward effects started to
surface. Allergic reactions, nephrogenic systemic sclerosis, and deposition in brain
tissue dented the safety profile of gadolinium-based contrast agent. Better understanding
of these adverse effects prompted preventive measures. This article elucidates the
gadolinium-based contrast agent toxicity in the pediatric population based on the
current available evidence.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Pediatric NeurologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Runge VM, Stewart RG, Clanton JA, et al. Potential oral and intravenous paramagnetic NMR contrast agents. Oral Presentation At: Radiological Society Of North America Annual Meeting, 1982; Chicago, IL.
- Enhanced Magnetic Resonance Imaging.C.V. Mosby Company, St. Louis, MO1989
- Gadolinium-based contrast agent-related toxicities.CNS Drugs. 2018; 32: 229-240
- Contrast-enhanced MRI. Evaluation of a canine model of osmotic blood-brain barrier disruption.Invest Radiol. 1985; 20: 830-844
- High-dose gadoteridol in MR imaging of intracranial neoplasms.J Magn Reson Imaging. 1992; 2: 9-18
- Detectability of early brain meningitis with magnetic resonance imaging.Invest Radiol. 1995; 30: 484-495
- Immediate Allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis.Radiology. 2018; 286: 731
- Gadolinium-based contrast agents: a comprehensive risk assessment.J Magn Reson Imaging. 2017; 46: 338-353
- Patterns of intravenous contrast material use and corticosteroid premedication in children—a survey of Society of Chairs of Radiology in Children's Hospitals (SCORCH) member institutions.Pediatr Radiol. 2011; 41: 1272-1283
- Safety of contrast material use in children.Magn Reson Imaging Clin N Am. 2017; 25: 779-785
- Safety of gadobutrol in more than 1,000 pediatric patients: subanalysis of the GARDIAN study, a global multicenter prospective non-interventional study.Pediatr Radiol. 2016; 46: 1317-1323
- Review of the current evidence on gadolinium deposition in the brain.Clin Neuroradiol. 2018; https://doi.org/10.1007/s00062-018-0678-0
- The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: a critical update.Crit Rev Toxicol. 2014; 44: 895-913
- Safe use of imaging contrast agents in children.J Am Coll Radiol. 2009; 6: 576-581
- Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults.AJR Am J Roentgenol. 2007; 189: 1533-1538
- Chasing contrast molecules: a 45-year quixotic quest.Acad Radiol. 2004; 11: 1190-1196
- Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?.Nephrol Dial Transplant. 2006; 21 (Erratum in: Nephrol Dial Transplant 21:1745): 1104-1108
- Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.J Am Soc Nephrol. 2006; 17: 2359-2362
- The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.Crit Rev Toxicol. 2014; 44: 895-913
- Gadolinium-based contrast agents: a comprehensive risk assessment.J Magn Reson Imaging. 2017; 46: 338-353
- Gadodiamide contrast agent ‘ activates ’ fibroblasts:a possible cause of nephrogenic systemic fibrosis.J Pathol. 2008; 21 (Erratum in: J Pathol 214:593): 584-593
- Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.Radiology. 2010; 256: 735-743
- Fibroblast response to gadolinium: role for platelet-derived growth factor receptor.Invest Radiol. 2010; 45: 769-777
Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis- a Mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 61: 537–552.
- Clinical, biological, and skin histopathologic eff ects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis.Invest Radiol. 2011; 46: 85-93
- The role of residual gadolinium in thei nduction of nephrogenic systemic fibrosis-like skin lesions in rats.Invest Radiol. 2011; 46: 48-56
- Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinfl ammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.J Immunol. 2012; 189: 318-327
- Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agent.Arthritis Rheum. 2009; 60: 1508-1518
- Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents.Clin Exp Immunol. 2014; 175: 113-125
- Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent.Invest Radiol. 2010; 45: 42-48
- Nephrogenic fibrosing dermopathy: two pediatric cases.J Pediatr. 2003; 143: 678-681
- Nephrogenic fibrosing dermopathy in pediatric patients.Pediatr Nephrol. 2004; 19: 467-470
- Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations.J Am Acad Dermatol. 2011; 65 (e7): 1095-1106
- Nephrogenic fibrosing dermopathy in children.Pediatr Nephrol. 2006; 21: 1307-1311
- Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report.Pediatr Radiol. 2014; 44: 173-180
- Gadolinium- based contrast agent accumulation and toxicity: an update.AJNR Am J Neuroradiol. 2016; 37: 1192-1198
- A review of the current evidence on gadolinium deposition in the brain.Clin Neuroradiol. 2018; https://doi.org/10.1007/s00062-018-0678-0
- Pediatric brain: repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging.Radiology. 2017; 282: 222-228
- Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams.Pediatr Radiol. 2016; 46: 1590-1598
- Pediatric patients demonstrate progressive T1-weighted hyperintensity in the dentate nucleus following multiple doses of gadolinium-based contrast agent.AJNR Am J Neuroradiol. 2016; 37: 2340-2347
- Gadolinium brain deposition after macrocyclic gadolinium administration: a pediatric case-control study.Radiology. 2017; 285: 223-230
- Pediatric brain: no increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images after consecutive exposure to a macrocyclic gadolinium-based contrast agent.Radiology. 2017; 283: 828-836
- Comparison of unenhanced T1-weighted signal intensities within the dentate nucleus and the globus pallidus after serial applications of gadopentetate dimeglumine versus gadobutrol in a pediatric population.Invest Radiol. 2018; 53: 119-127
- Pediatric Brain: Gadolinium deposition in dentate nucleus and globus pallidus on unenhanced T1-weighted images is dependent on the type of contrast agent.Invest Radiol. 2018; 53: 246-255
- Changes in signal intensity in the dentate nucleus at unenhanced T1-weighted magnetic resonance imaging depending on class of previously used gadolinium-based contrast agent.Pediatr Radiol. 2018; 48: 686-693
- Gadolinium deposition in the paediatric brain: T1-weighted hyperintensity within the dentate nucleus following repeated gadolinium-based contrast agent administration.Clin Radiol. 2018; 73: 290-295
- T1 signal measurements in pediatric brain: findings after multiple exposures to gadobenate dimeglumine for imaging of nonneurologic disease.AJNR Am J Neuroradiol. 2017; 38: 1799-1806
- Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children.Pediatr Radiol. 2017; 47: 1345-1352
- Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy.Acta Radiol. 2010; 51: 1126-1136
- Distribution map of gadolinium deposition within the cerebellum following GBCA administration.Neurology. 2017; 88: 1206-1208
- Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue.Eur Radiol. 2017; 27: 2877-2885
- Changes in background blood-brain barrier integrity between lacunar and cortical ischemic stroke subtypes.Stroke. 2008; 39: 1327-1332
- Improved HYDROPS: imaging of endolymphatic hydrops after intravenous administration of gadolinium.Magn Reson Med Sci. 2017; 16: 357-361
- A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β.Sci Transl Med. 2012; 4 (147ra111)
- Brain-wide pathway for waste clearance captured by contrast enhanced MRI.J Clin Invest. 2013; 123: 1299-1309
- Gadolinium retention, brain T1 hyperintensity, and endogenous metals: a comparative study of macrocyclic versus linear gadolinium chelates in renally sensitized rats.Invest Radiol. 2018; https://doi.org/10.1097/RLI.0000000000000447
- Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents.Radiology. 2017; 282: 516-525
- Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and macrocyclic gadolinium-based contrast agents.Invest Radiol. 2016; 51: 683-690
- Macrocyclic and other non-group 1 Gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue:preliminary results from 9 patients with normal renal function.Invest Radiol. 2016; 51: 447-453
- Gadolinium tissue deposition in brain and bone.Magn Reson Imaging. 2016; 34: 1359-1365
- Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities.Radiology. 2017; 285: 546-554
U.S. Food and Drug Administration. Center for Drug Evaluation and Research. FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI). 2015. http://www.fda.gov/Drugs/DrugSafety/ucm455386.htm#collapseOne. Accessed 21 April 2018.
- Gadolinium deposition in the brain: summary of evidence and recommendations.Lancet Neurol. 2017; 16: 564-570
- EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans.(Accessed 17 April 2018)
- Mono-, bi-, and trinuclear bis-hydrated Mn(2+) complexes as potential MRI contrast agents.Inorg Chem. 2015; 54: 9576-9587
- Low-molecular-weight iron chelates may be an alternative to gadolinium-based contrast agents for T1-weighted contrast-enhanced MR imaging.Radiology. 2018; 286: 537-546
- Nitroxide based macromolecular contrast agents with unprecedented transverse relaxivity and stability for magnetic resonance imaging of tumors.Acs Cent Sci. 2017; 3: 800-811
- The applicability of amide proton transfer imaging in the nervous system: focus on hypoxic-ischemic encephalopathy in the neonate.Cell Mol Neurobiol. 2018; 38: 797-807
- Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades.Neuro Oncol. 2014; 16: 441-448
- Advanced MRI for pediatric brain tumors with emphasis on clinical benefits.Korean J Radiol. 2017; 18: 194-207
Article info
Publication history
Published online: July 27, 2018
Accepted:
July 22,
2018
Received:
April 29,
2018
Footnotes
Disclosure of potential conflicts of interest: All the authors declare no conflicts of interest.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
